Alamar Biosciences, Inc.Alamar Biosciences, Inc.
ALMRHealth Care·Life Sciences Tools & Services
Alamar Biosciences, Inc. engages in developing a proteomic liquid biopsy platform and sells instruments, consumables & services for the early detection of diseases. Its products include ARGO HT system, NULISA assays for Immunology, neurology & oncology, NULISAqpcr custom assay development, technology access program and Alamar analysis solutions. The company was founded by Yuling Luo, Yiyuan Yin and Steve Chen in May 2018 and is headquartered in Fremont, CA.
Market cap
$1.8BNo data
Revenue
No dataNo data
Net income
No dataNo data
Free cash flow
No dataNo data
Substantial current assets relative to liabilities support high liquidity and short-term flexibility, while a positive gross margin contrasts with a negative operating margin and deployed capital converting into losses.
As of 2026-06-30Market
Listed stock
ALMRPriceNasdaqLoading…Loading…1Y